S Matthijs Boekholdt

List of Publications by Year
in descending order

250 papers	23,516 citations	13241 68 h-index	8486 147 g-index
256 all docs	256 docs citations	256 times ranked	29681 citing authors

#	Article	IF	Citations
1	Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 2010, 466, 707-713.	28.3	3,249
2	Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature Genetics, 2011, 43, 333-338.	21.7	1,685
3	Triglycerides and the Risk of Coronary Heart Disease. Circulation, 2007, 115, 450-458.	1.7	1,216
4	Association of LDL Cholesterol, Nonâ€“HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins. JAMA - Journal of the American Medical Association, 2012, 307, 1302.	7.6	650
5	Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet, The, 2010, 375, 1634-1639.	14.0	606
6	Serum Myeloperoxidase Levels Are Associated With the Future Risk of Coronary Artery Disease in Apparently Healthy Individuals. Journal of the American College of Cardiology, 2007, 50, 159-165.	2.8	544
7	Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events. Journal of the American College of Cardiology, 2014, 64, 485-494.	2.8	512
8	Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nature Genetics, 2011, 43, 1131-1138.	21.7	501
9	Body Fat Distribution and Risk of Coronary Heart Disease in Men and Women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk Cohort. Circulation, 2007, 116, 2933-2943.	1.7	407
10	Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment. Circulation, 2008, 117, 3002-3009.	1.7	405
11	Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes and Endocrinology,the, 2015, 3, 507-513.	11.7	389
12	Genetic Variants Influencing Circulating Lipid Levels and Risk of Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2264-2276.	2.4	369
13	Lipid-Related Markers and Cardiovascular Disease Prediction. JAMA - Journal of the American Medical Association, 2012, 307, 2499-506.	7.6	352
14	Genome-Wide Association Identifies Nine Common Variants Associated With Fasting Proinsulin Levels and Provides New Insights Into the Pathophysiology of Type 2 Diabetes. Diabetes, 2011, 60, 2624-2634.	0.6	335
15	High-Density Lipoprotein Cholesterol, High-Density Lipoprotein Particle Size, and Apolipoprotein A-I: Significance for Cardiovascular Risk. Journal of the American College of Cardiology, 2008, 51, 634-642.	2.8	330
16	Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment. Circulation, 2005, 111, 278-287.	1.7	302
17	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. European Heart Journal, 2014, 35, 960-968.	2.3	270
18	Beyond Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology, 2009, 55, 35-41.	2.8	268

#	Article	IF	Citations
19	Genetics, Clinical Features, and Long-TermÂOutcome of NoncompactionÂCardiomyopathy. Journal of the American College of Cardiology, 2018, 71, 711-722.	2.8	242
20	Value of Low-Density Lipoprotein Particle Number and Size as Predictors of Coronary Artery Disease in Apparently Healthy Men and Women. Journal of the American College of Cardiology, 2007, 49, 547-553.	2.8	225
21	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet, The, 2010, 376, 333-339.	14.0	221
22	Lipoprotein(a) Levels, Genotype, and Incident Aortic Valve Stenosis. Circulation: Cardiovascular Genetics, 2014, 7, 304-310.	5.1	219
23	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nature Communications, 2014, 5, 5068.	13.1	216
24	Variants of Toll-Like Receptor 4 Modify the Efficacy of Statin Therapy and the Risk of Cardiovascular Events. Circulation, 2003, 107, 2416-2421.	1.7	211
25	Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women. Circulation, 2004, 110, 1418-1423.	1.7	210
26	High-Density Lipoprotein Particle Size and Concentration and Coronary Risk. Annals of Internal Medicine, 2009, 150, 84.	4.0	201
27	Genetic Variation in Coagulation and Fibrinolytic Proteins and Their Relation With Acute Myocardial Infarction. Circulation, 2001, 104, 3063-3068.	1.7	195
28	Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With AorticÂStenosis. Journal of the American College of Cardiology, 2019, 73, 2150-2162.	2.8	187
29	Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. Circulation, 2016, 134, 1419-1429.	1.7	183
30	Lipid parameters for measuring risk of cardiovascular disease. Nature Reviews Cardiology, 2011, 8, 197-206.	13.9	177
31	IL-8 Plasma Concentrations and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1503-1508.	2.4	173
32	C-reactive protein is a mediator of cardiovascular disease. European Heart Journal, 2010, 31, 2087-2091.	2.3	164
33	Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients. Circulation, 2013, 128, 1504-1512.	1.7	162
34	Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy. Journal of the American College of Cardiology, 2013, 61, 148-152.	2.8	160
35	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nature Genetics, 2021, 53, 128-134.	21.7	155
36	C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: The EPIC-Norfolk prospective population study 1993â€“2003. Atherosclerosis, 2006, 187, 415-422.	0.8	153

#	Article	IF	Citations
37	The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk Prospective Population Study. Cmaj, 2010, 182, 1427-1432.	2.0	149
38	Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy. Circulation, 2012, 125, 1979-1987.	1.7	149
39	Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. Journal of Lipid Research, 2003, 44, 1080-1093.	4.2	147
40	Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 3058-3065.	2.4	146
41	Role of the Apolipoprotein Bâ€“Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Caseâ€“Control Analysis in EPIC-Norfolk. Annals of Internal Medicine, 2007, 146, 640.	4.0	140
42	Initial thyroid status and cardiovascular risk factors: The EPICâ€Norfolk prospective population study. Clinical Endocrinology, 2010, 72, 404-410.	2.6	140
43	Oxidation-Specific Biomarkers, Lipoprotein(a), and Risk of Fatal and Nonfatal Coronary Events. Journal of the American College of Cardiology, 2010, 56, 946-955.	2.8	139
44	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation, 2018, 138, 770-781.	1.7	126
45	Secretory Phospholipase A2-IIA and Cardiovascular Disease. Journal of the American College of Cardiology, 2013, 62, 1966-1976.	2.8	115
46	Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. Journal of Lipid Research, 2011, 52, 1829-1836.	4.2	113
47	PLA2G7 Genotype, Lipoprotein-Associated Phospholipase A ₂ Activity, and Coronary Heart Disease Risk in 10 494 Cases and 15 624 Controls of European Ancestry. Circulation, 2010, 121, 2284-2293.	1.7	111
48	Plasma levels of plant sterols and the risk of coronary artery disease: the prospective EPIC-Norfolk Population Study. Journal of Lipid Research, 2007, 48, 139-144.	4.2	105
49	Arterial Thrombosis and the Role of Thrombophilia. Seminars in Thrombosis and Hemostasis, 2007, 33, 588-596.	2.7	102
50	Apolipoprotein A-II Is Inversely Associated With Risk of Future Coronary Artery Disease. Circulation, 2007, 116, 2029-2035.	1.7	101
51	HDL particle size and the risk of coronary heart disease in apparently healthy men and women: The EPIC-Norfolk prospective population study. Atherosclerosis, 2009, 206, 276-281.	0.8	101
52	Inherited disorders of HDL metabolism and atherosclerosis. Current Opinion in Lipidology, 2005, 16, 139-145.	2.7	100
53	Serum Levels of Type II Secretory Phospholipase A2 and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 839-846.	2.4	100
54	Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. European Heart Journal, 2018, 39, 2589-2596.	2.3	100

#	Article	IF	Citations
55	Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1177-1183.	2.4	99
56	Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms. Circulation, 2010, 121, 52-62.	1.7	96
57	Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart, 2010, 96, 1985-1989.	3.0	96
58	Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. European Heart Journal, 2011, 32, 336-344.	2.3	93
59	On-Treatment Nonâ€“High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy. Journal of the American College of Cardiology, 2012, 59, 1521-1528.	2.8	90
60	ANGPTL4E40K and T266M. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 2319-2325.	2.4	89
61	Genetic Variation at the Phospholipid Transfer Protein Locus Affects Its Activity and High-Density Lipoprotein Size and Is a Novel Marker of Cardiovascular Disease Susceptibility. Circulation, 2010, 122, 470-477.	1.7	86
62	Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. Journal of Lipid Research, 2006, 47, 2064-2070.	4.2	84
63	The Association Between Circulating Lipoprotein(a) and Type 2 Diabetes: Is It Causal?. Diabetes, 2014, 63, 332-342.	0.6	82
64	Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke. Circulation Research, 2019, 125, 773-782.	4.6	78
65	Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: The EPIC-Norfolk Prospective Population study. American Journal of Medicine, 2004, 117, 390-397.	1.5	77
66	Aldosterone Pathway Blockade to Prevent Atrial Fibrillation: A Systematic Review and Meta-Analysis. International Journal of Cardiology, 2017, 231, 155-161.	1.8	75
67	Impact of physical activity on the risk of cardiovascular disease in middle-aged and older adults: EPIC Norfolk prospective population study. European Journal of Preventive Cardiology, 2018, 25, 200-208.	1.9	75
68	Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPICâ€Norfolk Prospective Population Study. Journal of Internal Medicine, 2007, 262, 678-689.	6.2	74
69	Community-Based Lifestyle Intervention in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2017, 70, 318-327.	2.8	72
70	Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-ÎºB Ligand and Risk for Coronary Events. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 975-980.	2.4	71
71	Non-high-density lipoprotein cholesterol. Current Opinion in Lipidology, 2015, 26, 502-510.	2.7	69
72	Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention. European Heart Journal, 2020, 41, 3998-4007.	2.3	68

#	Article	IF	Citations
73	Serum Lipoprotein Lipase Concentration and Risk for Future Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 637-642.	2.4	67
74	Physical inactivity, abdominal obesity and risk of coronary heart disease in apparently healthy men and women. International Journal of Obesity, 2010, 34, 340-347.	3.5	67
75	Habitual chocolate consumption and risk of cardiovascular disease among healthy men and women. Heart, 2015, 101, 1279-1287.	3.0	67
76	Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study. Atherosclerosis, 2017, 256, 47-52.	0.8	65
77	Cholesteryl Ester Transfer Protein (CETP) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 706-715.	2.4	64
78	Evaluation of the Framingham Risk Score in the European Prospective Investigation of Cancerâ€“Norfolk Cohort<subtitle>Does Adding Glycated Hemoglobin Improve the Prediction of Coronary Heart Disease Events?</subtitle>. Archives of Internal Medicine, 2008, 168, 1209.	3.8	64
79	The Relationship Between Plasma Angiopoietin-like Protein 4 Levels, Angiopoietin-like Protein 4 Genotype, and Coronary Heart Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2277-2282.	2.4	64
80	Ideal cardiovascular health and risk of cardiovascular events in the EPIC-Norfolk prospective population study. European Journal of Preventive Cardiology, 2016, 23, 986-994.	1.9	63
81	Red cell distribution width is associated with physical inactivity and heart failure, independent of established risk factors, inflammation or iron metabolism; the EPICâ€”Norfolk study. International Journal of Cardiology, 2013, 168, 3550-3555.	1.8	62
82	Serum Levels of Mannose-Binding Lectin and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2345-2350.	2.4	61
83	Thrombospondin-2 Polymorphism Is Associated With a Reduced Risk of Premature Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, e24-7.	2.4	60
84	CETP gene variation: relation to lipid parameters and cardiovascular risk. Current Opinion in Lipidology, 2004, 15, 393-398.	2.7	59
85	Plasma levels of lecithin:cholesterol acyltransferase and risk offuture coronary artery disease in apparently healthy men and women: aprospective case-control analysis nested in the EPIC-Norfolk populationstudy. Journal of Lipid Research, 2010, 51, 416-421.	4.2	58
86	Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. European Heart Journal, 2007, 28, 2770-2777.	2.3	57
87	Retinol-Binding Protein 4 and Prediction of Incident Coronary Events in Healthy Men and Women. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 255-260.	3.7	57
88	The Role of Non-HDL Cholesterol in Risk Stratification for Coronary Artery Disease. Current Atherosclerosis Reports, 2012, 14, 130-134.	4.8	56
89	Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1206-1212.	2.4	56
90	Bayesian Meta-Analysis of Genetic Association Studies with Different Sets of Markers. American Journal of Human Genetics, 2008, 82, 859-872.	6.4	54

#	Article	IF	Citations
91	Molecular variation at the apolipoproteinï¿½B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis. Human Genetics, 2003, 113, 417-425.	3.8	50
92	Both Paraoxonase-1 Genotype and Activity Do Not Predict the Risk of Future Coronary Artery Disease; the EPIC-Norfolk Prospective Population Study. PLoS ONE, 2009, 4, e6809.	2.5	48
93	Incremental diagnostic accuracy of hybrid SPECT/CT coronary angiography in a population with an intermediate to high pre-test likelihood of coronary artery disease. European Heart Journal Cardiovascular Imaging, 2013, 14, 642-649.	1.2	48
94	Detailed characterization of familial idiopathic ventricular fibrillation linked to the DPP6 locus. Heart Rhythm, 2016, 13, 905-912.	0.8	48
95	Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. European Heart Journal Cardiovascular Imaging, 2019, 20, 92-100.	1.2	48
96	Role of CETP inhibitors in the treatment of dyslipidemia. Current Opinion in Lipidology, 2004, 15, 631-636.	2.7	47
97	Aortic valve stenosis and aortic diameters determine the extent of increased wall shear stress in bicuspid aortic valve disease. Journal of Magnetic Resonance Imaging, 2018, 48, 522-530.	3.6	47
98	Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study. Heart, 2009, 95, 1682-1687.	3.0	46
99	Physical activity, metabolic syndrome, and coronary risk: the EPICâ€“Norfolk prospective population study. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 209-217.	2.8	46
100	Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels. Clinical Genetics, 2006, 69, 263-270.	2.1	45
101	Genetic and InÂVitro Inhibition of PCSK9 and Calcific Aortic Valve Stenosis. JACC Basic To Translational Science, 2020, 5, 649-661.	4.3	45
102	Estimated 10-year cardiovascular mortality seriously underestimates overall cardiovascular risk. Heart, 2016, 102, 63-68.	3.0	44
103	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. Journal of Clinical Lipidology, 2018, 12, 130-136.	1.5	44
104	Plasma concentrations of ascorbic acid and C-reactive protein, and risk of future coronary artery disease, in apparently healthy men and women: the EPIC-Norfolk prospective population study. British Journal of Nutrition, 2006, 96, 516-22.	2.4	44
105	Prolactin Levels and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women. Circulation: Cardiovascular Genetics, 2009, 2, 389-395.	5.1	43
106	The interleukin-6 pathway and atherosclerosis. Lancet, The, 2012, 379, 1176-1178.	14.0	43
107	Hybrid myocardial perfusion SPECT/CT coronary angiography and invasive coronary angiography in patients with stable angina pectoris lead to similar treatment decisions. Heart, 2013, 99, 188-194.	3.0	41
108	C-Reactive Protein, Fatal and Nonfatal Coronary Artery Disease, Stroke, and Peripheral Artery Disease in the Prospective EPIC-Norfolk Cohort Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2888-2894.	2.4	41

#	Article	IF	Citations
109	Lack of association between common genetic variation in endothelial lipase (LIPG) and the risk for CAD and DVT. Atherosclerosis, 2010, 211, 558-564.	0.8	39
110	High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. Heart, 2015, 101, 356-362.	3.0	39
111	Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: the EPIC-Norfolk prospective population study. European Heart Journal, 2016, 37, 880-889.	2.3	39
112	Effect of Losartan on Right Ventricular Dysfunction. Circulation, 2018, 137, 1463-1471.	1.7	39
113	High-Dose Statin Therapy in Patients With Stable Coronary Artery Disease. Circulation, 2013, 127, 2485-2493.	1.7	38
114	Comparison between Gradient Gel Electrophoresis and Nuclear Magnetic Resonance Spectroscopy in Estimating Coronary Heart Disease Risk Associated with LDL and HDL Particle Size. Clinical Chemistry, 2010, 56, 789-798.	3.2	36
115	Surgical versus percutaneous treatment of aortic coarctation: new standards in an era of transcatheter repair. Expert Review of Cardiovascular Therapy, 2012, 10, 1517-1531.	1.5	35
116	Association of Circulating Monocyte Chemoattractant Proteinâ€“1 Levels With Cardiovascular Mortality. JAMA Cardiology, 2021, 6, 587.	6.2	35
117	Plasma trimethylamine N-oxide (TMAO) levels predict future risk of coronary artery disease in apparently healthy individuals in the EPIC-Norfolk prospective population study. American Heart Journal, 2021, 236, 80-86.	2.8	35
118	Adiponectin and Risk of Coronary Heart Disease in Apparently Healthy Men and Women (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	34
119	Major Depression, C-Reactive Protein, and Incident Ischemic Heart Disease in Healthy Men and Women. Psychosomatic Medicine, 2008, 70, 850-855.	1.9	33
120	Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: The EPIC-Norfolk prospective population study. International Journal of Cardiology, 2010, 143, 399-404.	1.8	33
121	Advanced cardiac MRI techniques for evaluation of leftâ€sided valvular heart disease. Journal of Magnetic Resonance Imaging, 2018, 48, 318-329.	3.6	33
122	Genetic Variation in LPA, Calcific Aortic Valve Stenosis in Patients Undergoing Cardiac Surgery, and Familial Risk of Aortic Valve Microcalcification. JAMA Cardiology, 2019, 4, 620.	6.2	32
123	Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial. American Journal of Cardiovascular Drugs, 2020, 20, 73-80.	2.2	32
124	Association of FADS1/2 Locus Variants and Polyunsaturated Fatty Acids With Aortic Stenosis. JAMA Cardiology, 2020, 5, 694.	6.2	32
125	Added value of hybrid myocardial perfusion SPECT and CT coronary angiography in the diagnosis of coronary artery disease. European Heart Journal Cardiovascular Imaging, 2014, 15, 1281-1288.	1.2	31
126	Smoking cessation after an acute coronary syndrome: immediate quitters are successful quitters. Netherlands Heart Journal, 2015, 23, 600-607.	0.9	31

#	Article	IF	Citations
127	Lipoprotein(a) Improves Cardiovascular Risk PredictionÂBased on Established Risk Algorithms. Journal of the American College of Cardiology, 2017, 69, 1513-1515.	2.8	31
128	Elevated lipoprotein(a) levels are associated with coronary artery calcium scores in asymptomatic individuals with a family history of premature atherosclerotic cardiovascular disease. Journal of Clinical Lipidology, 2018, 12, 597-603.e1.	1.5	31
129	Impact of cholesterol on proinflammatory monocyte production by the bone marrow. European Heart Journal, 2021, 42, 4309-4320.	2.3	31
130	Lipid assessment, metabolic syndrome and coronary heart disease risk. European Journal of Clinical Investigation, 2010, 40, 1081-1093.	3.4	30
131	High-sensitivity Troponin T Is Associated with Poor Outcome in Adults with Pulmonary Arterial Hypertension due to Congenital Heart Disease. Congenital Heart Disease, 2013, 8, 520-526.	0.2	30
132	Effective components of nurse-coordinated care to prevent recurrent coronary events: a systematic review and meta-analysis. Heart, 2016, 102, 50-56.	3.0	30
133	Lipoprotein(a) is robustly associated with aortic valve calcium. Heart, 2021, 107, 1422-1428.	3.0	29
134	Physical activity, the Framingham risk score and risk of coronary heart disease in men and women of the EPIC-Norfolk study. Atherosclerosis, 2010, 209, 261-265.	0.8	28
135	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Journal of Medical Genetics, 2016, 53, 835-845.	3.3	28
136	Human Cardiac 31P-MR Spectroscopy at 3 Tesla Cannot Detect Failing Myocardial Energy Homeostasis during Exercise. Frontiers in Physiology, 2017, 8, 939.	2.8	28
137	Nonâ€‹<scp>HDL</scp> cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the <scp>EPIC</scp>â€Norfolk prospective population study. European Journal of Clinical Investigation, 2013, 43, 1009-1015.	3.4	27
138	Impact of High-Dose Atorvastatin Therapy and Clinical Risk Factors on Incident Aortic Valve Stenosis in Patients With Cardiovascular Disease (from TNT, IDEAL, and SPARCL). American Journal of Cardiology, 2014, 113, 1378-1382.	1.6	27
139	Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk?. Circulation, 2015, 132, 433-440.	1.7	27
140	Association of Long-term Exposure to Elevated Lipoprotein(a) Levels With Parental Life Span, Chronic Diseaseâ€“Free Survival, and Mortality Risk. JAMA Network Open, 2020, 3, e200129.	6.1	27
141	Dilation of the Aorta Ascendens Forms Part of the Clinical Spectrum of HCN4 Mutations. Journal of the American College of Cardiology, 2016, 67, 2313-2315.	2.8	25
142	Myocardial infarction with non-obstructive coronary arteries: aÂfocus on vasospastic angina. Netherlands Heart Journal, 2019, 27, 237-245.	0.9	25
143	CT angiography vs echocardiography for detection of cardiac thrombi in ischemic stroke: a systematic review and meta-analysis. Journal of Neurology, 2020, 267, 1793-1801.	3.7	25
144	Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. Journal of Lipid Research, 2016, 57, 697-705.	4.2	24

#	Article	IF	Citations
145	Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopyâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 43-48.	2.4	24
146	Câ€Reactive Protein Identifies Lowâ€Risk Metabolically Healthy Obese Persons: The European Prospective Investigation of Cancerâ€"Norfolk Prospective Population Study. Journal of the American Heart Association, 2016, 5, .	3.7	23
147	Novel Genetic Approach to Investigate the Role of Plasma Secretory Phospholipase A2 (sPLA) Tj ETQq1 1 0.784314 rgBT /Overlock 10 144-150.	5.1	22
148	The Systematic COronary Risk Evaluation (SCORE) in a large UK population: 10-year follow-up in the EPIC-Norfolk prospective population study. European Journal of Preventive Cardiology, 2015, 22, 119-126.	1.9	22
149	The prognostic value of heart rate recovery in patients with coronary artery disease: A systematic review and meta-analysis. American Heart Journal, 2018, 199, 163-169.	2.8	22
150	Interaction between a genetic variant of the platelet fibrinogen receptor and fibrinogen levels in determining the risk of cardiovascular events. American Heart Journal, 2004, 147, 181-186.	2.8	21
151	Fibrinogen plasma levels modify the association between the factor XIII Val34Leu variant and risk of coronary artery disease: the EPIC-Norfolk prospective population study. Journal of Thrombosis and Haemostasis, 2006, 4, 2204-2209.	3.9	21
152	Physical activity, C-reactive protein levels and the risk of future coronary artery disease in apparently healthy men and women: the EPICâ€"Norfolk prospective population study. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 970-976.	2.8	21
153	C-reactive protein and cardiovascular risk: more fuel to the fire. Lancet, The, 2010, 375, 95-96.	14.0	21
154	The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies. Circulation: Cardiovascular Genetics, 2012, 5, 51-57.	5.1	21
155	Rimonabant: obituary for a wonder drug. Lancet, The, 2010, 376, 489-490.	14.0	20
156	Life's simple 7 and calcific aortic valve stenosis incidence in apparently healthy men and women. International Journal of Cardiology, 2018, 269, 226-228.	1.8	19
157	Chemokine Ligand 2 Genetic Variants, Serum Monocyte Chemoattractant Protein-1 Levels, and the Risk of Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1460-1466.	2.4	18
158	apoB/apoAâ€I Ratio and Lp(a) Associations With Aortic Valve Stenosis Incidence: Insights From the EPICâ€Norfolk Prospective Population Study. Journal of the American Heart Association, 2019, 8, e013020.	3.7	18
159	Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis. Heart, 2022, 108, 61-66.	3.0	18
160	PLA2G10 Gene Variants, sPLA2 Activity, and Coronary Heart Disease Risk. Circulation: Cardiovascular Genetics, 2015, 8, 356-362.	5.1	17
161	An Evidence-Based Guide to Cholesterol-Lowering Guidelines. Canadian Journal of Cardiology, 2017, 33, 343-349.	1.7	16
162	Body mass index and body fat distribution and new-onset atrial fibrillation: Substudy of the European Prospective Investigation into Cancer and Nutrition in Norfolk (EPIC-Norfolk) study. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 692-700.	2.7	15

#	Article	IF	Citations
163	Standardizing the Cardiac Radioablation Targeting Workflow: Enabling Semi-Automated Angulation and Segmentation of the Heart According to the American Heart Association Segmented Model. Advances in Radiation Oncology, 2022, 7, 100928.	1.2	15
164	Inhibition of Lipoprotein-Associated Phospholipase Activity by Darapladib. Circulation, 2008, 118, 1120-1122.	1.7	14
165	Aortic dissection and prophylactic surgery in congenital heart disease. International Journal of Cardiology, 2019, 274, 113-116.	1.8	14
166	Relationship between In Vitro Lipopolysaccharide-Induced Cytokine Response in Whole Blood, Angiographic In-Stent Restenosis, and Toll-Like Receptor 4 Gene Polymorphisms. Clinical Chemistry, 2005, 51, 516-521.	3.2	13
167	Habitual chocolate consumption and the risk of incident heart failure among healthy men and women. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 722-734.	2.7	13
168	Association of Highâ€Density Lipoproteinâ€Cholesterol Versus Apolipoprotein Aâ€I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancerâ€Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. Journal of the American Heart Association, 2017, 6, .	3.7	13
169	Quantification of Mitral Valve Regurgitation from 4D Flow MRI Using Semiautomated Flow Tracking. Radiology: Cardiothoracic Imaging, 2020, 2, e200004.	2.6	13
170	A pooled-analysis of age and sex based coronary artery calcium scores percentiles. Journal of Cardiovascular Computed Tomography, 2020, 14, 414-420.	1.3	13
171	Lifestyle modification in older versus younger patients with coronary artery disease. Heart, 2020, 106, 1066-1072.	3.0	13
172	Tissue factor serum levels and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Journal of Thrombosis and Haemostasis, 2006, 4, 2391-2396.	3.9	12
173	Validation of a model to investigate the effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD: the rotterdam ischemic heart disease and stroke computer simulation (RISC) model. BMC Medicine, 2012, 10, 158.	5.6	12
174	Platypnoea-orthodeoxia syndrome, an underdiagnosed cause of hypoxaemia: four cases and the possible underlying mechanisms. Netherlands Heart Journal, 2015, 23, 539-545.	0.9	12
175	Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 213-221.	2.3	12
176	Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. Heart, 2018, 104, 1699-1705.	3.0	12
177	Myocardial fibrosis predicts adverse outcome after MitraClip implantation. Catheterization and Cardiovascular Interventions, 2019, 93, 1146-1149.	1.7	12
178	Lipoprotein-associated phospholipase A2 activity, genetics and calcific aortic valve stenosis in humans. Heart, 2020, 106, 1407-1412.	3.0	12
179	Fully quantitative mapping of abnormal aortic velocity and wall shear stress direction in patients with bicuspid aortic valves and repaired coarctation using 4D flow cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 9.	3.4	12
180	Community-based comprehensive lifestyle programs in patients with coronary artery disease: Objectives, design and expected results of Randomized Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists 2 trial (RESPONSE 2). American Heart Journal, 2015, 170, 216-222.	2.8	11

#	Article	IF	Citations
181	Four-dimensional flow MRI of stented versus stentless aortic valve bioprostheses. European Radiology, 2018, 28, 257-264.	4.6	11
182	Subclinical effects of longâ€chain fatty acid Î²â€oxidation deficiency on the adult heart: A caseâ€control magnetic resonance study. Journal of Inherited Metabolic Disease, 2020, 43, 969-980.	3.6	11
183	Outcomes of cardiac surgery after mediastinal radiation therapy: A singleâ€center experience. Journal of Cardiac Surgery, 2020, 35, 612-619.	0.7	11
184	Sex-Specific Associations of Genetically Predicted Circulating Lp(a) (Lipoprotein(a)) and Hepatic LPA Gene Expression Levels With Cardiovascular Outcomes: Mendelian Randomization and Observational Analyses. Circulation Genomic and Precision Medicine, 2021, 14, e003271.	3.5	11
185	Elixhauser Comorbidity Score Is the Best Risk Score in Predicting Survival After Mitraclip Implantation. Structural Heart, 2018, 2, 53-57.	0.6	10
186	Can stress echocardiography identify patients who will benefit from percutaneous mitral valve repair?. International Journal of Cardiovascular Imaging, 2019, 35, 645-651.	1.6	10
187	Percutaneous treatment of native aortic coarctation in adults. Netherlands Heart Journal, 2011, 19, 436-439.	0.9	9
188	Advanced therapy for pulmonary arterial hypertension due to congenital heart disease: a clinical perspective in a new therapeutic era. Netherlands Heart Journal, 2011, 19, 509-513.	0.9	9
189	Impact of abdominal obesity and systemic hypertension on risk of coronary heart disease in men and women. Journal of Hypertension, 2014, 32, 2224-2230.	0.5	9
190	Coronary artery calcification score as tool for risk assessment among families with premature coronary artery disease. Atherosclerosis, 2016, 245, 155-160.	0.8	9
191	Quantification of Myocardial Creatine and Triglyceride Content in the Human Heart: Precision and Accuracy of in vivo Proton Magnetic Resonance Spectroscopy. Journal of Magnetic Resonance Imaging, 2021, 54, 411-420.	3.6	9
192	Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention. Pharmacogenetics and Genomics, 2010, 20, 544-552.	1.6	8
193	Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?. Current Opinion in Cardiology, 2010, 25, 622-626.	1.8	8
194	Relationship between atorvastatin dose and the harm caused by torcetrapib. Journal of Lipid Research, 2012, 53, 2436-2442.	4.2	8
195	Transition from paediatric to adult care of adolescent patients with congenital heart disease: aÂpathway to optimal care. Netherlands Heart Journal, 2016, 24, 682-690.	0.9	8
196	Validation of the Systematic COronary Risk Evaluation - Older Persons (SCORE-OP) in the EPIC-Norfolk prospective population study. International Journal of Cardiology, 2019, 293, 226-230.	1.8	8
197	Smoking cessation after nurse-coordinated referral to a comprehensive lifestyle programme in patients with coronary artery disease: a substudy of the RESPONSE-2 trial. European Journal of Cardiovascular Nursing, 2019, 18, 113-121.	1.0	8
198	Aortic dissection masquerading as a code stroke: A single-centre cohort study. European Stroke Journal, 2020, 5, 56-62.	5.6	8

#	Article	IF	Citations
199	Prospective study of insulin-like growth factor-I, insulin-like growth factor-binding protein 3, genetic variants in the IGF1 and IGFBP3 genes and risk of coronary artery disease. International Journal of Molecular Epidemiology and Genetics, 2011, 2, 261-85.	0.4	8
200	Varespladib: targeting the inflammatory face of atherosclerosis. European Heart Journal, 2011, 32, 923-926.	2.3	7
201	De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough?. European Heart Journal, 2012, 33, 1548-1550.	2.3	7
202	Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study. Journal of Clinical Lipidology, 2018, 12, 1493-1501.e11.	1.5	7
203	Bileaflet mechanical aortic valves do not alter ascending aortic wall shear stress. International Journal of Cardiovascular Imaging, 2019, 35, 703-710.	1.6	7
204	Higher anticholinergic burden from medications is associated with significant increase in markers of inflammation in the EPICâ€Norfolk prospective populationâ€based cohort study. British Journal of Clinical Pharmacology, 2022, 88, 3297-3306.	2.5	7
205	Hypertriglyceridemic waist: missing piece of the global cardiovascular risk assessment puzzle?. Clinical Lipidology, 2011, 6, 639-651.	0.4	6
206	Per-operative stent placement in the right pulmonary artery; a hybrid technique for the management of pulmonary artery branch stenosis at the time of pulmonary valve replacement in adult Fallot patients. Netherlands Heart Journal, 2011, 19, 432-435.	0.9	6
207	Rates and determinants of progressive aortic valve dysfunction in aortic coarctation. International Journal of Cardiology, 2013, 167, 2841-2845.	1.8	6
208	Two cases of aorto-right atrial tunnel: clinical presentation, imaging and percutaneous closure. Netherlands Heart Journal, 2012, 20, 509-512.	0.9	5
209	Reply. Journal of the American College of Cardiology, 2013, 61, 1934.	2.8	5
210	Unroofed coronary sinus newly diagnosed in adult patients after corrected congenital heart disease. Netherlands Heart Journal, 2014, 22, 240-5.	0.9	5
211	Retrospective Cameraâ€Based Respiratory Gating in Clinical Wholeâ€Heart <scp>4D</scp> Flow <scp>MRI</scp>. Journal of Magnetic Resonance Imaging, 2021, 54, 440-451.	3.6	5
212	The impact and challenges of implementing CTCA according to the 2019 ESC guidelines on chronic coronary syndromes: a survey and projection of CTCA services in the Netherlands. Insights Into Imaging, 2021, 12, 186.	3.5	5
213	Zero coronary calcium in the presence of severe isolated left main stenosis detected by CT coronary angiography in a patient with typical angina and equivocal myocardial perfusion SPECT. Journal of Nuclear Cardiology, 2012, 19, 165-168.	2.2	4
214	Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study. European Heart Journal, 2013, 34, 1350-1357.	2.3	4
215	Usefulness of coronary calcium scoring to myocardial perfusion SPECT in the diagnosis of coronary artery disease in a predominantly high risk population. International Journal of Cardiovascular Imaging, 2013, 29, 677-684.	1.6	4
216	Nurse-coordinated care improves the achievement of LDL cholesterol targets through more intensive medication titration. Open Heart, 2017, 4, e000607.	2.3	4

#	Article	IF	Citations
217	The Dutch SCORE-based risk charts seriously underestimate theÂrisk of cardiovascular disease. Netherlands Heart Journal, 2017, 25, 173-180.	0.9	4
218	Abnormal blood flow and wall shear stress are present in corrected aortic coarctation despite successful surgical repair. Journal of Cardiovascular Surgery, 2019, 60, 152-154.	0.6	4
219	Mind the Heart: Electrocardiography-gated cardiac computed tomography-angiography in acute ischaemic strokeâ€"rationale and study design. European Stroke Journal, 2020, 5, 441-448.	5.6	4
220	Improving risk stratification for cardiovascular disease. Expert Review of Cardiovascular Therapy, 2010, 8, 1091-1093.	1.5	3
221	Patent ductus arteriosus in adults â€“ indications and possibilities for closure. Netherlands Heart Journal, 2011, 19, 297-300.	0.9	3
222	A comparative analysis of three widely used lipid management guidelines in the EPIC-Norfolk cohort. European Journal of Preventive Cardiology, 2013, 20, 98-106.	1.9	3
223	Clinical and Biological Relevance of Statin-Mediated Changes in HDL Metabolism. Current Atherosclerosis Reports, 2014, 16, 379.	4.8	3
224	Very low LDL-cholesterol concentrations achieved: which target is next?. Lancet, The, 2017, 390, 1930-1931.	14.0	3
225	Effect of Long-Term Low Lipoproteins on Neurocognitive Function. Journal of the American College of Cardiology, 2018, 72, 1176-1177.	2.8	3
226	A 3-SNP gene risk score and a metabolic risk score both predict hypertriglyceridemia and cardiovascular disease risk. Journal of Clinical Lipidology, 2019, 13, 492-501.	1.5	3
227	Baffle Complications in Adults After Atrial Switch for Transposition of the Great Arteries. Canadian Journal of Cardiology, 2022, 38, 68-76.	1.7	3
228	Is myeloperoxidase a useful marker to predict the risk of cardiovascular events?. Current Cardiovascular Risk Reports, 2009, 3, 137-143.	1.9	2
229	Response to letter by Balta et al.. International Journal of Cardiology, 2013, 169, 89.	1.8	2
230	Common genetic variants do not associate with CAD in familial hypercholesterolemia. European Journal of Human Genetics, 2014, 22, 809-813.	2.9	2
231	Response to â€œcomment on â€œaldosterone pathway blockade to prevent atrial fibrillation: A systematic review and meta-analysisâ€•by Neefs et al.â€•. International Journal of Cardiology, 2017, 242, 23.	1.8	2
232	Systolic anterior motion of the tricuspid valve in a patient with hypertrophic obstructive cardiomyopathy. Interactive Cardiovascular and Thoracic Surgery, 2017, 25, 496-497.	1.1	2
233	Association between serum secretory phospholipase A2 and risk of ischaemic stroke. European Journal of Neurology, 2021, 28, 3650-3655.	3.4	2
234	C-reactive protein measurement and cardiovascular disease â€“ Authors' reply. Lancet, The, 2010, 375, 1077-1078.	14.0	1

#	Article	IF	Citations
235	Percutaneous treatment of native aortic coarctation in adults. Netherlands Heart Journal, 2012, 20, 339-340.	0.9	1
236	The authorsâ€™ reply. Heart, 2013, 99, 1136.2-1137.	3.0	1
237	Coronary Artery Disease Affects Symptomatology of Aortic Valve Stenosis. Journal of the American College of Cardiology, 2017, 70, 1103-1104.	2.8	1
238	Advanced cardiac MRI techniques for evaluation of left-sided valvular heart disease. Journal of Magnetic Resonance Imaging, 2018, 48, spcone-spcone.	3.6	1
239	Comprehensive Lipid Profiling Beyond LDL. , 2011, , 107-118.		1
240	Midline crossing pulmonary vein: right upper lobe dual venous drainage, with partial anomalous venous return of the right lung into a persistent left superior vena cava. Surgical and Radiologic Anatomy, 2022, 44, 99-103.	1.3	1
241	Confirmatory factor analysis including MRI-derived adipose tissues quantification improves associations of metabolic dysregulation to diastolic dysfunction. Journal of Diabetes and Its Complications, 2022, 36, 108202.	2.4	1
242	Relationship of Sodium Intake With Granulocytes, Renal and Cardiovascular Outcomes in the Prospective EPICâ€Norfolk Cohort. Journal of the American Heart Association, 2022, 11, .	3.7	1
243	Lipid Parameters and Cardiovascular Events in Patients Taking Statinsâ€”Reply. JAMA - Journal of the American Medical Association, 2012, 308, 131.	7.6	0
244	Reply. Journal of the American College of Cardiology, 2015, 65, 109.	2.8	0
245	Different road maps for ventricular tachycardia ablation. Netherlands Heart Journal, 2020, 28, 571-572.	0.9	0
246	Multimodality Evaluation of a Septal Cystic Cavity and Ventricular Septal Defect in the Setting of Neurocysticercosis and Endocarditis. Circulation: Cardiovascular Imaging, 2021, 14, e011688.	2.5	0
247	Normalization of global longitudinal strain after a 30-seconds exercise bout in elite athletes. European Heart Journal, 2021, 42, .	2.3	0
248	Reduction of heart volume during neoadjuvant chemoradiation in patients with resectable esophageal cancer.. Journal of Clinical Oncology, 2014, 32, 4044-4044.	1.7	0
249	Response to: Correspondence on "Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis" by Pantelidis et al. Heart, 2022, 108, 576-577.	3.0	0
250	Abstract 11: Cardiac CT To Detect Cardiac Thrombi In Patients With Acute Ischemic Stroke: A Substudy Of Mind The Heart. Stroke, 2022, 53, .	2.0	0